Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

No One Seems Happy with Follow-on Biologics According to the FTC

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Kevin E. Noonan -- Last week, the Federal Trade Commission issued a report on follow-on biologics ("Emerging Health Care Issues: Follow-on Biologic Drug Competition"). As many patent practitioners did a few years ago when the FTC issued a report on patent reform, many in the biotech and pharma community, generics companies, and Congress are asking "What is the FTC camel's nose doing in our tent?" The report is extensive, covering the likely market impact of follow-on biologics (FOB) competition, the effects of patent protection and market incentives in the face of FOB introduction, the potential impact of a Hatch-Waxman-like...

Full post as published by Patent Docs on June 15, 2009 (boomark / email).